T0	Participants 61 128	acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
T1	Participants 130 331	Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses
T2	Participants 505 584	three of 25 patients given high-dose cytarabine and three of 23 given amsacrine